OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Saint Fleur-Lominy on Emerging Agents in MPNs

March 19th 2020

Shella Saint Fleur-Lominy, MD, PhD, an assistant professor in the Department of Medicine at NYU Langone Health

Dr. Le on Treatment Approaches for Oligometastatic Colorectal Cancer

March 19th 2020

Phat Le, MD, assistant professor, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses treatment approaches for patients with oligometastatic colorectal cancer (CRC).

Dr. Agarwal on Impact of the TITAN Trial With Apalutamide Plus ADT in mCSPC

March 18th 2020

Neeraj Agarwal, MD, discusses the impact of the TITAN trial in metastatic castration-sensitive prostate cancer.

Dr. Fendler on the Impact of 68Ga-PSMA-11 PET Imaging on Prostate Cancer Management

March 18th 2020

Wolfgang Fendler, MD, discusses the impact of 68Ga-PSMA-11 PET imaging on the clinical management of patients with prostate cancer.

Dr. Graff on the Safety of Checkpoint Inhibition in mCRPC

March 18th 2020

Julie N. Graff, MD, discusses the safety profile of pembrolizumab plus enzalutamide in patients with metastatic castration-resistant prostate cancer.

Dr. Grivas on PARP inhibition in Germline and DNA Damage Repair-Mutated mCRPC

March 18th 2020

Petros Grivas, MD, PhD, discusses PARP inhibition in patients with germline and somatic DNA damage repair-mutated metastatic castration-resistant prostate cancer.

Dr. Campbell on Precautions for Preventing Spread of COVID-19

March 18th 2020

Matthew T. Campbell, MD, MS, shares ways to prevent the spread of coronavirus 2019.

Dr. Cone on Cardiac Toxicity With GnRH Agonists in Prostate Cancer

March 18th 2020

Eugene B. Cone, MD, urologist, Massachusetts General Hospital, discusses the cardiac toxicity associated with gonadotropin-releasing hormone (GnRH) agonists in prostate cancer.

Dr. Miklos on the Results of the ZUMA-2 Trial in MCL

March 18th 2020

David Miklos, MD, discusses the results of the phase II ZUMA-2 trial with KTE-X19 in mantle cell lymphoma.

Dr. Abdul Hay on the Evolving Role of Transplant in ALL

March 18th 2020

Mohammad Maher Abdul Hay, MD, discusses the evolving role of transplant in acute lymphoblastic leukemia.

Dr. Bardia on the Potential Impact of COVID-19 on Immunocompromised Patients

March 18th 2020

Aditya Bardia, MD, MPH, discusses the potential impact of novel coronavirus on immunocompromised patients.

Dr. Cutler on Treatment Options for Acute and Chronic GVHD

March 18th 2020

Corey S. Cutler, MD, MPH, FRCPC, discusses treatment options for patients with acute and chronic graft-versus-host disease.

Dr. Westin on the Role of R-CHOP in DLBCL

March 18th 2020

Jason Westin, MD, MS, FACP, discusses the role of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in diffuse large B-cell lymphoma.

Dr. Agarwal on the COSMIC-021 Trial Design in Castration-Resistant Prostate Cancer

March 17th 2020

Neeraj Agarwal, MD, discusses the design of cohort 6 in the phase Ib COSMIC-021 trial in metastatic castration-resistant prostate cancer.

Dr. Fendler on the Utility of 68Ga-PSMA-11 PET in Prostate Cancer

March 17th 2020

Wolfgang Fendler, MD, discusses the utility of 68Ga-PSMA-11 PET in prostate cancer.

Dr. Abdul-Hay on Treatment Considerations in ALL

March 17th 2020

Mohammad Maher Abdul-Hay, MD, an assistant professor in the Department of Medicine; director of the Clinical Leukemia Program in NYU Langone Health’s Perlmutter Cancer Center; and associate director for research in the Bellevue Cancer Center, discusses treatment considerations in acute lymphoblastic leukemia (ALL).

Dr. Hamid on the Progression of Therapy for Metastatic Prostate Cancer

March 17th 2020

Anis Hamid, MBBS, discusses the progression of therapy for metastatic prostate cancer.

Dr. Hamdan on Trial of Brentuximab Vedotin/Chemo in HIV-Associated Hodgkin Lymphoma

March 17th 2020

Ayad Hamdan, MD, hematologist and associate professor of medicine at Moores Cancer Center at the University of California, San Diego, discusses a pilot phase I/II trial with brentuximab vedotin (Adcetris) plus chemotherapy in patients with HIV-associated Hodgkin lymphoma.

Dr. Grossbard on the GALLIUM Study in Follicular Lymphoma

March 17th 2020

Michael L. Grossbard, MD, professor in the Department of Medicine, chief of the Hematology and Medical Oncology Inpatient Service at Tisch Hospital, and section chief of Hematology at NYU Langone Health’s Perlmutter Cancer Center, discusses the results of the phase III GALLIUM study in follicular lymphoma.

Dr. Mesa on the Utility of Fedratinib for Patients With Myelofibrosis Who Progress on Ruxolitinib

March 16th 2020

Ruben Mesa, MD, discusses the utility of fedratinib for patients with myelofibrosis who progress on first-line ruxolitinib.